

January 22, 2015



AxoGen, Inc. to Host Surgeon Education Event at AAHS ASPN ASRM Joint 2015 Annual Meeting

Company to exhibit nerve repair portfolio at Booth T35 & T36.

Alachua, FL (PRWEB) January 22, 2015

AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum for surgeons at the Joint Annual Meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve and American Society for Reconstructive Microsurgery, taking place January 21-27 in Paradise Island, Bahamas.

The event, entitled “The Value of Nerve Repair Technologies in Your Practice” will focus on improving outcomes in surgical nerve repair, anesthesiology planning, considerations for O.R. time management and evidence based treatment algorithms. Surgeon panelists will include Greg Buncke, MD, Buncke Clinic; Jeff Greenberg, MD, Indiana Hand to Shoulder Center; and Dean Sotereanos, MD, University of Pittsburgh Medical Center. The panel presentation will be held on Thursday, January 22nd at 1:30 PM.

In addition to sponsoring this surgeon educational forum, AxoGen will be exhibiting its full portfolio of nerve repair and protection products at Booth T35 & T36 at the AAHS ASPN ASRM Joint Meetings.

About this Event

Panel Presentation: The Value of Nerve Repair Technologies in Your Practice

Date: Thursday, January 22, 2015; 1:30 – 3:00pm

Panelists: Greg Buncke, MD, Jeff Greenberg, MD, Dean Sotereanos, MD

Location: AAHS Annual Meeting, Paradise Island, Bahamas, Ballroom AB

Surgeon Registration Click here: <http://www.axogeninc.com/aahs-aspn-asrm/>

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for

tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

To learn more about AxoGen and to sign up for our news alerts, visit our website at <http://www.AxoGenInc.com>.

Cautionary Statement Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.